Novel options for failing allograft in kidney transplanted patients to avoid or defer dialysis therapy
Current Opinion in Nephrology and Hypertension, ISSN: 1473-6543, Vol: 29, Issue: 1, Page: 80-91
2020
- 9Citations
- 1Usage
- 26Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef7
- Usage1
- Abstract Views1
- Captures26
- Readers26
- 26
Review Description
Purpose of reviewDespite improvement in short-Term renal allograft survival in recent years, renal transplant recipients (RTR) have poorer long-Term allograft outcomes. Allograft function slowly declines with periods of stable function similar to natural progression of chronic kidney disease in nontransplant population. Nearly all RTR transitions to failing renal allograft (FRG) period and require transition to dialysis. Conservative chronic kidney disease management before transition to end-stage renal disease is an increasingly important topic; however, there is limited data in RTR regarding how to delay dialysis initiation with conservative management.Recent findingsSince immunological and nonimmunological factors unique to RTR contribute to decline in allograft function, therapies to slow progression of FRG should take both sets of factors into account. Renal replacement therapy either incremental dialysis or rekidney transplantation should be explored. This required taking benefits and risks of continuing immunosuppressive medications into account when allograft nephrectomy may be necessary.SummaryFRG may benefit from various interventions to slow progression of worsening allograft function. Until there are stronger evidence to guide interventions to preserve renal function, extrapolating evidence from nontransplant patients and clinical judgment are necessary. The goal is to provide individualized care for conservative management of RTR with FRG.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85075962146&origin=inward; http://dx.doi.org/10.1097/mnh.0000000000000572; http://www.ncbi.nlm.nih.gov/pubmed/31743241; http://journals.lww.com/00041552-202001000-00012; https://scholarlyworks.beaumont.org/nephrology_articles/17; https://scholarlyworks.beaumont.org/cgi/viewcontent.cgi?article=1016&context=nephrology_articles; https://dx.doi.org/10.1097/mnh.0000000000000572; https://journals.lww.com/co-nephrolhypertens/Abstract/2020/01000/Novel_options_for_failing_allograft_in_kidney.12.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know